0 41

Cited 0 times in

Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention

Authors
 Jung Ha Park  ;  Ju Young Kim  ;  Jong Han Choi  ;  Hye Soon Park  ;  Hyun-Young Shin  ;  Jae Min Lee  ;  Jin-Wook Kim  ;  Hae-Jin Ko  ;  Suk Chon  ;  Bu Kyung Kim  ;  Chul Sik Kim  ;  Soo Lim 
Citation
 INTERNATIONAL JOURNAL OF OBESITY, Vol.45(4) : 776-786, 2021-04 
Journal Title
INTERNATIONAL JOURNAL OF OBESITY
ISSN
 0307-0565 
Issue Date
2021-04
MeSH
Adult ; Blood Pressure ; Body Mass Index ; Body Weight ; Exercise ; Female ; Heart Disease Risk Factors ; Humans ; Life Style* ; Liraglutide / therapeutic use* ; Male ; Middle Aged ; Obesity / therapy* ; Republic of Korea ; Weight Loss*
Abstract
Objective: We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.

Methods: People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.

Results: The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m2, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m2 at 2 months; -4.23 kg and -1.55 kg/m2 at 4 months, and -5.14 kg and -1.89 kg/m2 at 6 months (all P < 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%).

Conclusions: In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.
Full Text
https://www.nature.com/articles/s41366-021-00739-z
DOI
10.1038/s41366-021-00739-z
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chul Sik(김철식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190966
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links